SCHEMBL2043091

SCHEMBL2043091

COc1cc(NCc2cccc(F)c2O)cc(Br)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.47
KMT2A Q03164 7/20 0.47
MEN1 O00255 6/20 0.47
KDM4E B2RXH2 5/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ALOX15 P16050 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 11/20 0.44
ALDH1A1 P00352 8/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 3/20 0.44
LMNA P02545 3/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2041882 0.86 CA12 (0.46) MAPTKMT2AMEN1KDM4ENPSR1
SCHEMBL2040730 0.83 PDE2A (0.39) MAPTKMT2AMEN1KDM4ENPSR1
SCHEMBL2044273 0.82 NOX4 (0.49) MAPTKMT2AMEN1KDM4ENPSR1
SCHEMBL2041372 0.82 GAA (0.47) MAPTKMT2AMEN1KDM4ENPSR1
SCHEMBL2038649 0.80 MAP2K4 (0.41) MAPTKMT2AMEN1KDM4EALOX15
SCHEMBL2042919 0.79 MEN1 (0.41) MAPTKMT2AMEN1KDM4ENPSR1
SCHEMBL2041507 0.78 KMT2A (0.42) MAPTKMT2AMEN1KDM4ENPSR1
SCHEMBL17556537 0.76 AR (0.37) MAPTKMT2AMEN1KDM4ENPSR1
SCHEMBL13506675 0.75 HTR2A (0.45) MAPTKMT2AMEN1KDM4ENPC1
SCHEMBL13506591 0.73 MPO (0.44) MAPTKMT2AMEN1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US claimed
EP-2516400-B1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2017-03-22 EP claimed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US claimed
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-02-12 US disclosed
EP-2516400-B1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RES & DEV (FR) 2017-03-22 EP disclosed
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF COLLETTE PATRICE LUCIEN MAURICE (FR) 2016-03-10 US disclosed
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-07-11 US disclosed
EP-2516400-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF Galderma Research & Development (FR) 2012-10-31 EP disclosed
WO-2011077046-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068488-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA MAPT 761/4885KMT2A 2277/4885MEN1 3059/4885
US-20130178633-A1 PHENOL DERIVATIVES AND THE PHARMACEUTICAL OR COSMETIC USE THEREOF TYR, MITF, CUTA MAPT 761/4885KMT2A 2277/4885MEN1 3059/4885
US-10202346-B2 Phenol derivatives and the pharmaceutical or cosmetic use thereof TYR, MITF, CUTA MAPT 761/4885KMT2A 2277/4885MEN1 3059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.